

Prescriber Criteria Form  
Tabrecta 2026 PA Fax 3879-A v1 010126.docx  
Tabrecta (capmatinib)  
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Tabrecta (capmatinib).

Drug Name:  
Tabrecta (capmatinib)

<b>Patient Name:</b>		
<b>Patient ID:</b>		
<b>Patient DOB:</b>	<b>Patient Phone:</b>	
<b>Prescriber Name:</b>		
<b>Prescriber Address:</b>		
<b>City:</b>	<b>State:</b>	<b>Zip:</b>
<b>Prescriber Phone:</b>	<b>Prescriber Fax:</b>	
<b>Diagnosis:</b>	<b>ICD Code(s):</b>	

**Please circle the appropriate answer for each question.**

1	Does the patient have a diagnosis of central nervous system (CNS) brain metastases from mesenchymal-epithelial transition (MET) exon-14 mutated non-small cell lung cancer (NSCLC)? [If yes, then no further questions.]	Yes	No
2	Does the patient have a diagnosis of non-small cell lung cancer (NSCLC)? [If no, then no further questions.]	Yes	No
3	Does the patient have high-level mesenchymal-epithelial transition (MET) amplification? [If yes, then no further questions.]	Yes	No
4	Does the patient have recurrent, advanced, or metastatic disease? [If no, then no further questions.]	Yes	No
5	Is the patient's tumor positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutation?	Yes	No

Comments: \_\_\_\_\_

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

**Prescriber (or Authorized) Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_